ClinicalTrials.Veeva

Menu

Hearing Screening Outcomes of Two Screening Tests in Newborns of Gestational Diabetic Mothers

A

Ankara Training and Research Hospital

Status

Completed

Conditions

Gestational Diabetes
Hearing Loss

Treatments

Diagnostic Test: Hearing screening tests

Study type

Observational

Funder types

Other

Identifiers

NCT04845412
CGDMP2020

Details and patient eligibility

About

In this study, the investigators have aimed to investigate whether GDM is a risk factor for hearing impairment in newborns. To the investigators knowledge, this study is the first prospective, controlled study on this subject.

Full description

Gestational diabetes mellitus (GDM) is an increasingly frequent condition in the world causing significant morbidity and mortality. GDM is a metabolic disease that develops in pregnancy, and may result in complications in the pregnant women, similar to other patients with diabetes. The prevalence of GDM varies in relation with the population and the diagnostic criteria. Diabetes affects 6-9% of pregnant women; 99% of the cases have GDM, and diabetes is diagnosed before pregnancy in the remaining 1% [(pre-gestational diabetes mellitus (pre-GDM)]. Hearing loss is one of the most common birth defect in newborns. The incidence of congenital hearing impairment is 2-3 per 1000 births. Early diagnosis and treatment is very important for the development of auditory pathways and protection of cognitive functions. Therefore, newborn hearing screening programs have been in use in a number of countries. Transient evoked otoacoustic emissions (TEOAE) and auditory brainstem response (ABR) have been identified as basic convenient and applicable tools for neonatal screening of hearing.

Suboptimal glycemic control during pregnancy has adverse fetal effects. Congenital malformations, preterm birth and neonatal respiratory distress in the newborn are more common, at varying rates, pre-GDM and GDM. Compared to the normal population, the risk of congenital malformations is 1.9-10 fold higher in presence of pre-GDM, and 1.1-1.3 fold higher in presence of GDM. Despite our awareness on these important complications, the effect of intrauterine hyperglycemia on hearing of the newborn has not yet been studied in detail. Diabetes mellitus (DM) often causes hearing impairment, however little is known whether GDM is an antenatal risk factor for cochlear damage and hearing loss.

Enrollment

114 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Women with gestational diabetes
  • Women without diabetic pregnancy

Exclusion criteria

  • Admitted to the neonatal intensive care unit for more than five days
  • Perinatal asphyxia
  • Craniofacial abnormalities
  • İntrauterine infections
  • Hyperbilirubinemia requiring exchange transfusion
  • Very low birth weight (<1500 g)
  • Gestational hypertension
  • Preeclampsia

Trial design

114 participants in 2 patient groups

Children of GDM parents
Description:
Children of mothers who have gestational diabetes mellitus
Treatment:
Diagnostic Test: Hearing screening tests
Children of non-diabetic parents
Description:
Children of mothers without diabetes
Treatment:
Diagnostic Test: Hearing screening tests

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems